EUVIMEDEUVIMED entdecken
Open Access

An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum

Rex Devasahayam Arokia Balaya, Partho Sen, Caroline W Grant, Roman Zenka, Marimuthu Sappani, Jeyaseelan Lakshmanan, Arjun P Athreya, Richard K Kandasamy, Akhilesh Pandey iD, Seul Kee Byeon

Journal of Gastroenterology · 2025-04 · 60 (4) · 496-511

DOI: 10.1007/s00535-024-02197-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, online erschienen am 12.12.2024. Verfasst von Rex Devasahayam Arokia Balaya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a formidable health challenge due to its detection at a late stage and a lack of reliable biomarkers for early detection. Although levels of carbohydrate antigen 19-9 are often used in conjunction with imaging-based tests to aid in the diagnosis of PDAC, there is still a need for more sensitive and specific biomarkers for early detection of PDAC. METHODS: We obtained serum samples from 88 subjects (patients with PDAC (n = 58) and controls (n = 30)). We carried out a multi-omics analysis to measure cytokines and related proteins using proximity extension technology and lipidomics and metabolomics using tandem mass spectrometry. Statistical analysis was carried out to find molecular alterations in patients with PDAC and a machine learning model was used to derive a molecular signature of PDAC. RESULTS: We quantified 1,462 circulatory proteins along with 873 lipids and 1,001 metabolites. A total of 505 proteins, 186 metabolites and 33 lipids including bone marrow stromal antigen 2 (BST2), keratin 18 (KRT18), and cholesteryl ester(20:5) were found to be significantly altered in patients. We identified different levels of sphingosine, sphinganine, urobilinogen and lactose indicating that glycosphingolipid and galactose metabolisms were significantly altered in patients compared to controls. In addition, elevated levels of diacylglycerols and decreased cholesteryl esters were observed in patients. Using a machine learning model, we identified a signature of 38 biomarkers for PDAC, composed of 21 proteins, 4 lipids, and 13 metabolites. CONCLUSIONS: Overall, this study identified several proteins, metabolites and lipids involved in various pathways including cholesterol and lipid metabolism to be changing in patients. In addition, we discovered a multi-analyte signature that could be further tested for detection of PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalBiomarkers, TumorHumansMaleFemaleMiddle AgedMetabolomicsAgedCase-Control StudiesTandem Mass SpectrometryMachine LearningLipidomicsEarly Detection of CancerLipidsCytokinesMultiomics

Stichwörter der Autor:innen

BiomarkersMulti-omics analysisPancreatic cancerPathogenesisSerum

Substanzen

Biomarkers, TumorLipidsCytokines

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
  • Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.
  • Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, 632002, India.
  • College of Medicine, Mohammad Bin Rashid University of Medicine and Health Sciences, Dubai, 505055, UAE.
  • Center for Individualized Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
  • Manipal Academy of Higher Education, Manipal, Karnataka, 5761904, India.

ORCID-Profile: Akhilesh Pandey

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Benefactor Funded Champions for Hope Pancreatic Cancer Award

Zitieren

APA

Devasahayam Arokia Balaya, R., Sen, P., Grant, C. W., Zenka, R., Sappani, M., Lakshmanan, J., Athreya, A. P., Kandasamy, R. K., Pandey, A., & Byeon, S. K. (2025). An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum. Journal of Gastroenterology, 60(4), 496-511. https://doi.org/10.1007/s00535-024-02197-6

Vancouver

Devasahayam Arokia Balaya R, Sen P, Grant CW, Zenka R, Sappani M, Lakshmanan J, et al. An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum. Journal of Gastroenterology. 2025;60(4):496-511. doi:10.1007/s00535-024-02197-6

BibTeX
@article{DevasahayamArokiaBalaya2025,
  author = {Devasahayam Arokia Balaya, Rex and Sen, Partho and Grant, Caroline W and Zenka, Roman and Sappani, Marimuthu and Lakshmanan, Jeyaseelan and Athreya, Arjun P and Kandasamy, Richard K and Pandey, Akhilesh and Byeon, Seul Kee},
  title = {An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum},
  journal = {Journal of Gastroenterology},
  year = {2025},
  volume = {60},
  number = {4},
  pages = {496--511},
  doi = {10.1007/s00535-024-02197-6}
}
Kostenlos starten →